DeciBio Culture

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors in Europe. A subscription to this report includes 2 waves of data, collected biannually.

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors. A subscription to this report includes 4 waves of data, collected on a quarterly basis (4 reports total, delivered once a quarter).

Blood-based biomarkers are emerging in neurodegenerative disease testing, enabling earlier, less invasive detection and monitoring. This analysis maps activity across clinical trials, publications, pharma pipelines, and routine clinical use to benchmark key biomarkers, disease focus areas, and leading industry players driving this shift.

After several years of muted growth from 2022 to 2025, the next-generation sequencing (NGS) market is finally set up for a recovery. We forecast that the ~$7.3B WW NGS manufacturer market (2025) will grow 7% p.a. to reach $8.9B in 2028.